NMDP Creates New Leadership Role to Accelerate Cell Therapy Adoption
Event summary
- NMDP appoints Ginna Laport, MD, as senior vice president of strategic, scientific and clinical partnerships.
- New role focuses on expanding partnerships to accelerate cell therapy adoption and patient access.
- Dr. Laport brings three decades of experience in academic medicine, biotech, and pharma.
- She previously served as chief medical officer at CARGO Therapeutics and held senior roles at Genentech/Roche.
The big picture
NMDP's appointment of Dr. Laport underscores the growing intersection between nonprofit healthcare and commercial biotech, as cell therapy adoption requires both clinical innovation and scalable access models. The move aligns with NMDP's five-year strategy to impact 10,000 patients annually, reflecting broader industry trends toward collaborative research and accelerated therapeutic development.
What we're watching
- Partnership Strategy
- How NMDP's new leadership will drive collaborations to expand patient access and clinical practice adoption.
- Regulatory Dynamics
- Whether Dr. Laport's FDA approval experience will streamline NMDP's regulatory pathways for cell therapies.
- Execution Risk
- The pace at which NMDP can integrate Dr. Laport's industry expertise into its nonprofit model.
Our editorial coverage: